J Blostein1, P A Clark. 1. Division of Immunization, Michigan Department of Community Health, Lansing, MI 48909, USA. blosteinj@state.mi.us
Abstract
OBJECTIVE: The goals of this study were to estimate seroprevalence of prior hepatitis B infection among high-risk adolescents and to determine the cost-effectiveness of prevaccination immunity screening. METHODS: The authors computed a "break-even" seroprevalence level calculated from current vaccine and administration costs. They then conducted a seroprevalence study of hepatitis B core antibody using sera previously submitted for syphilis serology from four-hundred adolescent and adult clients of sexually transmitted disease clinics. Finally, the authors compared age group-specific seroprevalence rates to the computed break-even seroprevalence. RESULTS: Levels of prior hepatitis B infection for all age groups were lower than the break-even seroprevalence standard from which cost-effectiveness was calculated. CONCLUSIONS: From the findings of this study, the authors concluded that routine preimmunization screening for prior hepatitis B infection would not be cost-effective for this population.
OBJECTIVE: The goals of this study were to estimate seroprevalence of prior hepatitis B infection among high-risk adolescents and to determine the cost-effectiveness of prevaccination immunity screening. METHODS: The authors computed a "break-even" seroprevalence level calculated from current vaccine and administration costs. They then conducted a seroprevalence study of hepatitis B core antibody using sera previously submitted for syphilis serology from four-hundred adolescent and adult clients of sexually transmitted disease clinics. Finally, the authors compared age group-specific seroprevalence rates to the computed break-even seroprevalence. RESULTS: Levels of prior hepatitis B infection for all age groups were lower than the break-even seroprevalence standard from which cost-effectiveness was calculated. CONCLUSIONS: From the findings of this study, the authors concluded that routine preimmunization screening for prior hepatitis B infection would not be cost-effective for this population.
Authors: G M McQuillan; P J Coleman; D Kruszon-Moran; L A Moyer; S B Lambert; H S Margolis Journal: Am J Public Health Date: 1999-01 Impact factor: 9.308
Authors: M'Kiaira K Miriti; Kaafee Billah; Cindy Weinbaum; Julie Subiadur; Richard Zimmerman; Paula Murray; Robert Gunn; Joanna Buffington Journal: Public Health Rep Date: 2008 Jul-Aug Impact factor: 2.792